Drugs / GT103
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT04314089 | Jun 2020 → Apr 2024 | non-small cell lung carcinoma | Edward Patz | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT07017829 | Apr 2026 → Dec 2028 expected | non-small cell lung carcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05617313 | Feb 2023 → Jun 2025 | non-small cell lung carcinoma | Jeffrey Clarke | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04314089 ↗ |
| Modality | Monoclonal antibody | “fully human, IgG3 monoclonal antibody” PMID 39747856 ↗ Jan 2025 |
| Route | Intravenous | “GT103 given intravenously at 0.3, 1, 3, 10, and 15 mg/kg every 3 weeks” PMID 39747856 ↗ Jan 2025 |
| Target | CFH | “GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H” PMID 39747856 ↗ Jan 2025 |